Back to results
US 2009/0246204 A1Published application
Use of a cd28 binding substance for making a pharmaceutical composition
AssigneeTegenero AG
InventorThomas Hunig
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimicry compound hereto for making a pharmaceutical composition for the induction and/or multiplication of regulatory T cells.
Claims10
A method for the treatment or prophylaxis of autoimmune diseases or inflammatory reactions, wherein a pharmaceutical composition for the induction or multiplication of regulatory T cells in vitro or in vivo.
A method for the treatment or prophylaxis of autoimmune diseases or inflammatory reactions, wherein either
- a pharmaceutical composition is administered to a patient, comprising a CD28-specific superagonistic monoclonal antibody or a mimicry compound hereto and in a galenic preparation for a defined and suitable form of administration comprising intraveneous injection;
- or
- a body liquid is taken from a patient, comprising blood comprising T lymphocytes or precursor cells hereto, and the body liquid, possibly after a processing step, is reacted with a CD28-specific superagonistic monoclonal antibody or a mimicry compound hereto, and the thus treated body liquid is again administered to the patient.
Dependencies are inferred from the claim text.